Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UX-DA003 is an allogeneic cell therapy candidate developed by UniXell Biotechnology for the treatment of Parkinson's disease. It consists of human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic neural precursor cells. The therapy is designed as an "off-the-shelf" product, utilizing donor-derived cells that are differentiated into neural precursors. Upon transplantation into the patient's brain, these cells are intended to mature into functional dopaminergic neurons, replacing the cells lost to neurodegeneration and restoring dopamine levels in the striatum. This approach aims to provide a scalable alternative to autologous therapies. UX-DA003 has received Investigational New Drug (IND) approval for clinical evaluation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UX-DA003.